Frailty and Treatment-Resistant Schizophrenia: A Retrospective Cohort Study

被引:10
|
作者
Pearson, Ella [1 ]
Siskind, Dan [2 ,4 ]
Hubbard, Ruth [3 ,4 ]
Gordon, Emily [3 ,4 ]
Coulson, Elizabeth [1 ]
Arnautovska, Urska [4 ]
Warren, Nicola [2 ,3 ,4 ]
机构
[1] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia
[2] Metro South Addict & Mental Hlth Serv, Brisbane, Qld, Australia
[3] Princess Alexandra Hosp, Dept Geriatr, 199 Ipswich Rd, Brisbane, Qld, Australia
[4] Univ Queensland, Fac Med, Brisbane, Qld, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
Frailty; Schizophrenia; Treatment-resistant; Severe mental illness; CLOZAPINE; INDEX; MANAGEMENT; HEALTH;
D O I
10.1007/s10597-022-00998-8
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Frailty, a state of reduced physiological reserve, has not been studied in consumers with treatment-resistant schizophrenia, despite known elevated rates of comorbidity and psychosocial impairment. This study applies a frailty index to the electronic medical records of 78 adults with treatment-resistant schizophrenia, aged 18-64 years, to determine the prevalence and characteristics of frailty (defined as a frailty index score > 0.21). The mean frailty index score was 0.24 (SD = 0.091, range = 0.061-0.54), with 52.6% of the population categorised as frail (40.0% in those aged 18-39 years). Frailty was positively correlated with age and psychiatric illness severity. This study provides novel evidence that individuals with treatment-resistant schizophrenia have a high rate of frailty and become frail at a younger age. Routine frailty assessments could be used to trigger the delivery of appropriate interventions, which have the potential to improve life expectancy and quality of life.
引用
收藏
页码:105 / 109
页数:5
相关论文
共 50 条
  • [21] Galantamine for treatment-resistant schizophrenia
    Allen, TB
    McEvoy, JP
    AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (07): : 1244 - 1245
  • [22] Treatment-resistant schizophrenia.
    Lublin, H
    NORDIC JOURNAL OF PSYCHIATRY, 1997, 51 : 9 - 23
  • [23] Treatment paradigms for treatment-resistant schizophrenia
    Lim, Carol
    Donovan, Abigail
    LANCET PSYCHIATRY, 2024, 11 (07): : 488 - 489
  • [24] Treatment-resistant schizophrenia in intellectual disabilities: a case study
    Hemmings, Colin
    Inwang, Francis
    Gravestock, Shaun
    Diaz, Zurima Toloza
    Lawson, Larte
    Walker, Nicky
    ADVANCES IN MENTAL HEALTH AND INTELLECTUAL DISABILITIES, 2011, 5 (02) : 35 - 40
  • [25] STUDY DEMONSTRATES EFFICACY OF CLOZAPINE IN TREATMENT-RESISTANT SCHIZOPHRENIA
    不详
    CLINICAL PHARMACY, 1988, 7 (12): : 858 - 858
  • [26] Comparison of the effects of quetiapine and haloperidol in a cohort of patients with treatment-resistant schizophrenia
    Buckley, PF
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 221 - 221
  • [27] Continuation ECT in treatment-resistant schizophrenia: A controlled study
    Chanpattana, W
    Chakrabhand, S
    Sackeim, HA
    Kitaroonchai, W
    Kongsakon, R
    Techakasem, P
    Buppanharun, W
    Tuntirungsee, Y
    Kirdcharoen, N
    JOURNAL OF ECT, 1999, 15 (03) : 178 - 192
  • [28] Pharmacogenetic Study of Treatment-Resistant Schizophrenia in a Mexican Population
    Nicolini, Humberto
    Martinez Magana, Jose Jaime
    Lanzagorta, Nuria
    Escamilla, Michael
    Genis Mendoza, Alma Delia
    Gonzalez-Covarrubias, Vanessa
    Soberon, Xavier
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S406 - S407
  • [29] A study of enhanced management in patients with treatment-resistant schizophrenia
    Mercer, G
    Finlayson, A
    Johnstone, EC
    Murray, C
    Owens, DGC
    JOURNAL OF PSYCHOPHARMACOLOGY, 1997, 11 (04) : 349 - 356
  • [30] Treatment-resistant schizophrenia and depression: "A Brazilian study with clozapine"
    Henna, J
    Elkis, H
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 231 - 232